NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) released its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.11). View Innovate Biopharmaceuticals' Earnings History.

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Innovate Biopharmaceuticals.

1 analysts have issued 1 year target prices for Innovate Biopharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Innovate Biopharmaceuticals' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 1,685.7% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

News coverage about INNT stock has been trending very negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a news sentiment score of -4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Innovate Biopharmaceuticals.

Innovate Biopharmaceuticals saw a increase in short interest in February. As of February 14th, there was short interest totalling 1,850,000 shares, an increase of 10.1% from the January 30th total of 1,680,000 shares. Based on an average daily volume of 727,800 shares, the short-interest ratio is presently 2.5 days. Currently, 8.1% of the shares of the stock are short sold. View Innovate Biopharmaceuticals' Current Options Chain.

Some companies that are related to Innovate Biopharmaceuticals include Immunic (IMUX), Sesen Bio (SESN), Checkpoint Therapeutics (CKPT), Neos Therapeutics (NEOS), AVEO Pharmaceuticals (AVEO), Menlo Therapeutics (MNLO), VERONA PHARMA P/S (VRNA), Elite Pharmaceuticals (ELTP), Axovant Gene Therapies (AXGT), Chembio Diagnostics (CEMI), Catalyst Biosciences (CBIO), Entasis Therapeutics (ETTX), Infinity Pharmaceuticals (INFI), Synlogic (SYBX) and Trevena (TRVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Innovate Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.20%). Company insiders that own Innovate Biopharmaceuticals stock include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Institutional Ownership Trends for Innovate Biopharmaceuticals.

INNT stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Innovate Biopharmaceuticals stock in the last two years include Christopher P Prior, Jay P Madan, June Sherie Almenoff, Roy Proujansky and Sandeep Laumas. View Insider Buying and Selling for Innovate Biopharmaceuticals.

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNT stock can currently be purchased for approximately $0.56.

Innovate Biopharmaceuticals has a market capitalization of $20.10 million. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]